ω-Substituted alkyl carboxylic acids as antidiabetic and lipid-lowering agents

European Journal of Medicinal Chemistry

Volumn 33, Issue 10, 1998, Pages 775-787

  Meyer, Kirstin ^b   Voss, Edgar ^a   Neidlein, Richard ^b   Kühnle, Hans Frieder ^a   Pill, Johannes ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Insulin sensitizer; Lipid lowering; substituted alkyl carboxylic acids

Indexed keywords

2,2 DICHLORO 12 (4 CHLOROPHENYL)DODECANOIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CARBOXYLIC ACID DERIVATIVE; CIGLITAZONE; PIOGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; STRUCTURE ACTIVITY RELATION;

EID: 0032320969     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(99)80029-4     Document Type: Article

References (36)

1. [1] DeFronzo R.A., Diabetologia 35 (1992) 389-397.
2. [2] Trischitta V., Frittitta L., Vigneri R., Diabetes/Metab. Rev. 13 (1997) 147-162.
3. [3] DeFronzo R.A., Ferrannini E., Diabetes Care 14 (1991) 173-194.
4. [4] Reaven G.M., Diabetes 37 (1988) 1595-1607.
5. [5] Anderson S., Vora J.P., J. Diab. Comp. 9 (1995) 304-307.
6. [6] Saltiel A.R., Olefsky J.M., Diabetes 45 (1996) 1661-1669.
7. [7] Panten U., Diabetes Stoffwechsel 1 (1992) 240-242.
8. [8] Klip A., Leiter L.A., Diabetes Care 13 (1990) 696-704.
9. [9] Chang A.Y., Wyse B.M., Diabetes 32 (1983) 830-838.
10. [10] Sohoda T. et al., Arzneim. Forsch. 40 (1990) 37-42.
11. [11] Stevenson R.W. et al., Diabetes 39 (1990) 1218-1227.
12. [12] Fujiwara T., Yoshioka S., Yoshioka T. et al., Diabetes 37 (1988) 1549-1558.
13. [13] Fujiwara T., Wada M., Fukuda K. et al., Metabolism 40 (1991) 1213-1218.
14. [14] Long S.D., Pekala P.H., J. Biol. Chem. 271 (1996) 1138-1144.
15. [15] Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkinson W.O., Willson T.M., Kliewer S.A., J. Biol. Chem. 270 (1995) 12953-12956.
16. [16] Auwerx J., Martin G., Guerre-Millo M., Staels B., J. Mol. Med. 74 (1996) 347-352.
17. [17] Gimble J.M. et al., Mol. Pharmacol. 50 (1996) 1087-1094.
18. [18] Spencer C.M., Markham A., Drugs 54 (1997) 89-101.
19. [19] Leutenegger M. et al., Curr. Ther. Res. 58 (1997) 403-416.
20. [20] Okuno G., Oki A., Kawakami F., Diabetes 40 (Suppl. 1) (1991) 343A.
21. [21] Kuzuya T. et al., Diabetes Res. Clin. Practice 11 (1991) 147-154.
22. [22] Suter S.L., Nolan J.J., Wallace P., Gumbiner B., Olefsky J.M., Diabetes Care 15 (1992) 193-203.
23. [23] Fouquet G., Schlosser M., Angew. Chemie 86 (1974) 50-51.
24. [24] Tamura M., Kochi J., Synthesis (1971) 303-305.
25. [25] Friedman L., Shani A., J. Am. Chem. Soc. 96 (1974) 7101-7103.
26. [26] Kahn C.R., Diabetes 43 (1994) 1066-1084.
27. [27] Spady D.K., Dietschy J.M., J. Lipid Res. 24 (1983) 303-315.
28. [28] Andersen J.M., Dietschy J.M., J. Lipid Res. 20 (1979) 740-752.
29. [29] Pill J. et al., Cytotechnology 1 (1988) 275-283.
30. [30] Herberg L., Coleman D.L., Metabolism 26 (1977) 59-99.
31. [31] Bar-Tana J., Ben-Shoshan S. et al., J. Med. Chem. 32 (1989) 2072-2084.
32. [32] Berry M.N., Friend D.S., J. Cell Biol. 43 (1969) 506-520.
33. [33] Morton H.J., In Vitro 6 (1970) 89-108.
34. [34] Pill J., Johne G., Stegmeier K., Frey A., Frey B., Schmidt F.H., Fresenius Z. Anal. Chem. 322 (1985) 512-513.
35. [35] Bergmeyer H.U., Methoden der Enzymatischen Analyse, Verlag Chemie, Weinheim, 1974, pp. 1241-1246.
36. [36] Wahlefeld A.W., In: Bergmeyer H.U. (Ed.), Methoden der Enzymatischen Analyse, Verlag Chemie, Weinheim, 1974, pp. 1878-1882.